Select Page

​APR Corp. Unveils Stunning ​Q3 Earnings: Beauty Tech Dominance Pays Off!

APR Corp., the beauty technology powerhouse, has stunned the market with its impressive performance in the third quarter of ​2023. The company has reported a remarkable surge in ​revenue and ​operating profit, surpassing all expectations and solidifying its standing as a leading player in the industry.

With a jaw-dropping year-over-year increase of 28%, APR Corp.’s revenue skyrocketed to an astounding KRW 122 billion ($94.8 million). But that’s not all – the company’s operating profit witnessed an almost unbelievable surge of nearly 73%, reaching a whopping KRW 21.7 billion ($16.87 million). These incredible figures were unveiled on Monday, leaving investors and competitors alike in awe.

Fueling APR Corp.’s remarkable growth is its beauty division, which continues to excel. The division’s medicube cosmetics line and AGE-R devices have been instrumental in driving the company’s success, with unit sales soaring to a staggering 750,000 in the exhilarating third quarter alone. This represents an impressive increase of almost 50% compared to the previous year. Notably, standout products like the Booster Healer device and Zero Pore Pads have played a significant role in this triumphant journey.

But it’s not just individual products that have contributed to APR Corp.’s triumphant earnings. The company’s well-established brands, including APRILSKIN and FORMENT, have showcased an impressive consistent year-over-year growth rate of around one-third. This steady performance has been a vital catalyst in APR Corp.’s expansion and unwavering success.

As the beauty technology sector continues to flourish, APR Corp. remains at the forefront, consistently delivering innovative and sought-after solutions. With their stunning Q3 performance, APR Corp. has proven that its dominance in the industry is not for show – it’s a force to be reckoned with, leaving competitors green with envy.

Dow futures dip, volume to return after Thanksgiving holidays

US stock futures were trading slightly lower during Sunday’s evening trade, after major benchmark averages closed their fourth consecutive week of gains.

By 6:30 pm GMT (11:30 pm GMT) Dow Jones Futures and S&P 500 Futures were down by 0.1% apiece while Nasdaq 100 Futures lost 0.2%.

In the week ahead, market participants will be closely monitoring building permits, new home sales, house price index, CB consumer confidence, GDP, PCE price index, personal income and spending, jobless claims, pending home sales, and manufacturing PMI data, as well as speeches from Waller, Bowman, Barr, Mester, Goolsbee and Powell.

Wall Street is riding on the momentum of a four-week winning streak for all three major averages. This rally has been fueled by the 10-year Treasury yield’s retreat from the 5% threshold it briefly surpassed in late October.

However, the rally comes amidst cautionary signals from some US retailers about a potential slowdown in consumer spending. Market traders are also keenly awaiting economic updates on the commencement of the holiday shopping season following Black Friday.

On the bond markets, United States 10-Year rates were at 4.492% while 2-year yields were at 4.955%.


​Domvanalimab Shows Promise in Treating Lung and Gastrointestinal Cancers Within a Competitive Anti-TIGIT Market

​Arcus Biosciences’ ​Phase 3 cancer immunotherapy drug, Domvanalimab, has demonstrated promising results in the treatment of ​lung and ​gastrointestinal cancers. Domvanalimab, an anti-TIGIT drug, has shown potential in clinical trials as an effective immunotherapy treatment for these types of cancers.

The Phase 3 trials conducted by Arcus Biosciences have shown positive outcomes, indicating that Domvanalimab may be a valuable addition to the treatment options available for lung and gastrointestinal cancers. However, it is important to note that the anti-TIGIT market is highly competitive, with several pharmaceutical companies investing in the development of drugs targeting this immune checkpoint protein.

In terms of financial performance, Arcus Biosciences experienced a slight drop in revenue and increased net loss in the third quarter of 2023. The company reported revenues of $32 million, compared to $33 million in the same period last year. Additionally, Arcus Biosciences reported a net loss of $71 million for the quarter, up from $65 million in the previous year.

After indulging in a week of ​turkey-induced comas and ​cranberry sauce confessions, it’s time to give thanks for the opportunity to invest wisely in the financial feast that lies ahead. While the leftovers are being reheated, let’s heat up our portfolios with a side dish of strategic investments. Just like ​Aunt Mildred’s famous ​pumpkin pie, the key ingredients to successful investing are patience, a dash of risk-taking, and a generous sprinkling of financial savvy. So, put on your ​stretchy pants, because we’re about to devour some appetizing returns. Remember, in the world of investing, it’s not about gobbling up every opportunity, but carefully selecting the juiciest prospects. So grab a plate, load up on potential, and let’s dig into the post-Thanksgiving investing feast!